The study characterized plasma cell-free DNA (cfDNA) variants of tumor, CH or germline origin in 16,812 patients with advanced cancer using Caris Assure, which sequences both the plasma and buffy ...
IRVING, Texas, Feb. 6, 2025 /PRNewswire/ -- Caris Life Sciences ® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, announced today that the company and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback